⌘K

Login Start Free

Home/Filings/4/0001250853-14-000035

4//SEC Filing

Galena Biopharma, Inc. 4

Accession 0001250853-14-000035

$SLSCIK 0001390478operating

View on SEC.gov Company Profile

Filed

Jan 28, 7:00 PM ET

Accepted

Jan 29, 9:34 PM ET

Size

23.8 KB

Accession

0001250853-14-000035

Insider Transaction Report

Form 4

Period: 2014-01-27

Galena Biopharma, Inc.GALE

Director

Transactions

Exercise/Conversion
Stock Option
2014-01-27−324,890→ 25,110 total
Exercise: $1.38Exp: 2021-03-30→ Common Stock (324,890 underlying)
Exercise/Conversion
Common Stock
2014-01-27$2.31/sh+50,000$115,500→ 163,764 total
Exercise/Conversion
Common Stock
2014-01-27$1.38/sh+100,000$138,000→ 263,764 total
Exercise/Conversion
Common Stock
2014-01-27$1.38/sh+324,890$448,348→ 588,654 total
Exercise/Conversion
Common Stock
2014-01-27$0.72/sh+200,000$144,000→ 788,654 total
Exercise/Conversion
Common Stock
2014-01-27$1.71/sh+121,875$208,406→ 918,529 total
Sale
Common Stock
2014-01-27$4.83/sh−796,765$3,848,375→ 113,764 total
Exercise/Conversion
Stock Option
2014-01-27−50,000→ 0 total
Exercise: $2.31Exp: 2021-01-13→ Common Stock (50,000 underlying)
Exercise/Conversion
Stock Option
2014-01-27−100,000→ 0 total
Exercise: $1.38From: 2011-03-31Exp: 2021-03-30→ Common Stock (100,000 underlying)
Exercise/Conversion
Stock Option
2014-01-27−200,000→ 200,000 total
Exercise: $0.72Exp: 2022-01-12→ Common Stock (200,000 underlying)
Exercise/Conversion
Stock Option
2014-01-27−121,875→ 423,173 total
Exercise: $1.71Exp: 2023-01-29→ Common Stock (121,875 underlying)

Footnotes (5)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $5.09 per share. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F2]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/13/11).
[F3]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (3/31/11).
[F4]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/12/12).
[F5]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/29/13).

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

Galena Biopharma, Inc.

CIK 0001390478

Entity typeoperating

IncorporatedDE

Related Parties

1

filerCIK 0001390478

Filing Metadata

Form type: 4
Filed: Jan 28, 7:00 PM ET
Accepted: Jan 29, 9:34 PM ET
Size: 23.8 KB

View on SEC.gov